Literature DB >> 8316806

Renal stone formation in patients with inflammatory bowel disease.

R Caudarella1, E Rizzoli, L Pironi, N Malavolta, G Martelli, G Poggioli, G Gozzetti, M Miglioli.   

Abstract

Kidney stones are more common in patients with inflammatory bowel disease (IBD) than in the general population. The main lithogenetic risk factors were evaluated in patients affected by Crohn's disease and ulcerative colitis. Our results show the presence of several factors, besides hyperoxaluria, in patients with IBD although their behaviour appears different in Crohn's disease and ulcerative colitis at pre- and post-operative stages. Before surgery in patients with Crohn's disease we found a decreased citrate (p < 0.001) and magnesium (p < 0.005) excretion together with a low urinary volume (p < 0.001) and pH (p < 0.005). After surgery patients with Crohn's disease showed a further reduction of magnesium and citrate. Patients with ulcerative colitis before surgery showed a reduced citrate excretion (p < 0.05) and a more acidic pH (p < 0.05) than healthy subjects. Surgical treatment of proctocolectomy with ileal pouch-anal anastomosis seems to increase the risk of stone formation; in fact, after surgery we observed a relevant decrease of urinary volume (p < 0.001), pH (p < 0.0001) and urinary excretion of citrate (p < 0.0001) as well as magnesium (p < 0.005). Patients with IBD seem to be at greater risk of stone formation than patients with idiopathic calcium lithiasis; in fact, they show a lower excretion of citrate (p < 0.001) and magnesium (p < 0.001) together with a low urinary pH (p < 0.001) and volume (p < 0.001). Urinary volume reduction is probably one of the major risk factors together with the decrease of small molecular weight inhibitors that is a constant finding in all patients with IBD.

Entities:  

Mesh:

Year:  1993        PMID: 8316806

Source DB:  PubMed          Journal:  Scanning Microsc        ISSN: 0891-7035


  21 in total

Review 1.  Extraintestinal manifestations in inflammatory bowel disease.

Authors:  Silvio Danese; Stefano Semeraro; Alfredo Papa; Italia Roberto; Franco Scaldaferri; Giuseppe Fedeli; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells.

Authors:  Donna Arvans; Yong-Chul Jung; Dionysios Antonopoulos; Jason Koval; Ignacio Granja; Mohamed Bashir; Eltayeb Karrar; Jayanta Roy-Chowdhury; Mark Musch; John Asplin; Eugene Chang; Hatim Hassan
Journal:  J Am Soc Nephrol       Date:  2016-10-13       Impact factor: 10.121

3.  Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease.

Authors:  Renate Hueppelshaeuser; Gerd E von Unruh; Sandra Habbig; Bodo B Beck; Stephan Buderus; Albrecht Hesse; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2012-02-25       Impact factor: 3.714

Review 4.  Stone formation and management after bariatric surgery.

Authors:  Sarah Tarplin; Vishnu Ganesan; Manoj Monga
Journal:  Nat Rev Urol       Date:  2015-04-07       Impact factor: 14.432

5.  miR-125a-5p: a novel regulator of SLC26A6 expression in intestinal epithelial cells.

Authors:  Arivarasu N Anbazhagan; Shubha Priyamvada; Alip Borthakur; Seema Saksena; Ravinder K Gill; Waddah A Alrefai; Pradeep K Dudeja
Journal:  Am J Physiol Cell Physiol       Date:  2019-05-01       Impact factor: 4.249

6.  Adenosinergic signaling inhibits oxalate transport by human intestinal Caco2-BBE cells through the A2B adenosine receptor.

Authors:  Daniel Jung; Altayeb Alshaikh; Sireesha Ratakonda; Mohamed Bashir; Ruhul Amin; Sohee Jeon; Jan Stevens; Sapna Sharma; Wahaj Ahmed; Mark Musch; Hatim Hassan
Journal:  Am J Physiol Cell Physiol       Date:  2018-07-18       Impact factor: 4.249

7.  Comorbidities in adolescents with inflammatory bowel disease: findings from a population-based cohort study.

Authors:  Itai Ghersin; Neron Khateeb; Lior H Katz; Saleh Daher; Raanan Shamir; Amit Assa
Journal:  Pediatr Res       Date:  2019-12-04       Impact factor: 3.756

Review 8.  Enteric hyperoxaluria: an important cause of end-stage kidney disease.

Authors:  Lama Nazzal; Sonika Puri; David S Goldfarb
Journal:  Nephrol Dial Transplant       Date:  2015-02-20       Impact factor: 5.992

9.  Extracellular nucleotides inhibit oxalate transport by human intestinal Caco-2-BBe cells through PKC-δ activation.

Authors:  Ruhul Amin; Sapna Sharma; Sireesha Ratakonda; Hatim A Hassan
Journal:  Am J Physiol Cell Physiol       Date:  2013-04-17       Impact factor: 4.249

Review 10.  Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Authors:  Ammon B Peck; Benjamin K Canales; Cuong Q Nguyen
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.